Jill Wechsler, Pharm Exec's Washington Correspondent

Jill Wechsler is Pharm Exec's Washington Corespondent


New Drug Approvals On Track at FDA

FDA is on track this year to authorize a notable number of new molecular entities and important biotech therapies.

Drug Prices Targeted in Biden Competition Initiative

A broad White House proposal to advance competition in major U.S. industries features several measures intended to make medicines more affordable for patients.

Woodcock Seeks Outside Investigation to Restore FDA Credibility

FDA acting commissioner Janet Woodcock has bowed to pressure and called on the HHS’s Office of the Inspector General to examine the review process for Biogen’s Alzheimer’s disease treatment, Aduhelm.